The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Biomarkers to Guide Diagnosis, Treatment of Rheumatic Diseases

Biomarkers to Guide Diagnosis, Treatment of Rheumatic Diseases

January 1, 2015 • By Rick Brasington, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Everybody is talking about biomarkers!

You Might Also Like
  • Letters: Biomarkers for Rheumatoid Arthritis
  • Progress Slow in Development of Useful Biomarkers for Rheumatoid Arthritis Treatment
  • Biomarkers May Help Differentiate Crohn’s From Colitis
Explore This Issue
January 2015
Also By This Author
  • What the Healthcare System Can Learn from the World of Bees

What is a biomarker? According to the NIH Biomarkers Definitions Working Group in 1998, a biomarker is:

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathological processes, or pharmacologic responses to a therapeutic intervention.

The ideal biomarker would:

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
  • Be safe and easy to measure;
  • Be sensitive and specific for the disease in question;
  • Be consistent across gender and ethnic groups;
  • Be cost efficient;
  • Provide more information than we have now; and
  • Be modifiable with treatment.

Figure 1: Biomarkers Used to Predict Each DAS28-CRP Component
click for large version
Figure 1: Biomarkers Used to Predict Each DAS28-CRP Component
Biomarkers used to estimate each component of the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) in the multibiomarker disease activity (MBDA) algorithm. The algorithm uses different subsets of biomarkers and/or different weightings to predict each component of the DAS28-CRP, including the tender joint count (TJC), swollen joint count (SJC), patient global assessment (PG), and CRP level. The resulting mathematical relationship between the DAS28-CRP and MBDA score is: MBDA = (DAS28-CRP) × 10.53 + 1. PTJC = predicted TJC; PSJC = predicted SJC; PPG = predicted PG; TJC28 = 28-joint TJC; SJC28 = 28-joint SJC; VEGF-A = vascular endothelial growth factor A; VCAM-1 = vascular cell adhesion molecule 1; IL-6 = interleukin-6; SAA1 = serum amyloid A1; EGF = epidermal growth factor; TNFRI = tumor necrosis factor receptor type I; MMP-1 = matrix metalloproteinase 1.

Source: Curtis JR, van der Helm-van Mil AH, Knevel R, et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 2012 Dec;64(12):1794–1803.

Whether you know it or not, you are already using “biomarkers” every day—blood pressure, lipid levels and glycosylated hemoglobin, to name just a few. In fact, in the treatment of rheumatoid arthritis (RA), you are undoubtedly using erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), and anticitrullinated protein antibodies (ACPA aka anti-CCP). Perhaps you even use Health Assessment Questionnaire (HAQ), RAPID-3 or Disease Activity Score (DAS) in its various iterations (Simplified DAS or SDAS, or Clinical DAS or CDAS).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

With respect to RA, we use the biomarkers we have to:

  • Identify patients with early RA;
  • Predict which patients will have severe disease with radiographic progression (RP);
  • Predict which patient will respond to which medications, especially biologic DMARDs;
  • Predict who will have toxicity to specific medications; and
  • Identify adequate response to medications.

Drawbacks of Current Biomarkers

To some extent, current biomarkers are helpful, but there are significant deficiencies. For example, ESR and CRP are elevated in only 40–50% of RA patients, which limits their application to half our patients. The relationship of CRP to RA disease activity is inconsistent. The Consortium of Rheumatology Researchers of North America (CORRONA) published in 2014 a study of 9,135 patients in their registry, in which they explored the relationship of the Clinical Disease Activity Index (CDAI) to CRP. The CDAI was derived from the more complicated DAS by eliminating the CRP or ESR value, as well as the complex formula for calculation. In patients with high disease activity by CDAI, neither ESR nor CRP was elevated in almost half of patients, and in patients with LOW disease activity, either ESR or CRP was elevated in a third. Therefore, we cannot adequately assess disease activity by the ESR or CRP.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Biomarker, Brasington, Clinical, patient care, Rheumatic Disease, Rheumatoid arthritisIssue: January 2015

You Might Also Like:
  • Letters: Biomarkers for Rheumatoid Arthritis
  • Progress Slow in Development of Useful Biomarkers for Rheumatoid Arthritis Treatment
  • Biomarkers May Help Differentiate Crohn’s From Colitis
  • More Evidence Biomarkers Predict RA Relapse with DMARD Taper

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.